Fresenius SE & Co. KGaA, commonly referred to as Fresenius, is a leading global healthcare group headquartered in Germany. Established in 1912, the company has evolved into a prominent player in the medical, precision, and optical instruments sector, particularly within the fields of dialysis, hospital management, and infusion therapies.
With a strong presence in Europe, North America, and Asia, Fresenius is renowned for its innovative products and services, including dialysis machines and nutritional solutions, which are distinguished by their high quality and reliability. The company has achieved significant milestones, including advancements in renal care and hospital services, solidifying its market position as a trusted provider in the healthcare industry. Fresenius continues to set benchmarks in patient care and medical technology, reflecting its commitment to improving health outcomes worldwide.
+54 vs industry average
Fresenius’s score of 83 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Fresenius?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Medical Device Manufacturing has below-average carbon intensity
Industry performance
The Medical Device Manufacturing industry has reduced its overall emissions by 32% since 2018
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Fresenius's reported carbon emissions
Fresenius, a DE-based company in the Medical, precision and optical instruments, watches and clocks (33) industry, reported a total of approximately 4.26 billion kg CO2e in emissions for 2025. This figure encompasses Scope 1, 2, and 3 emissions. In 2024, their total emissions were approximately 4.29 billion kg CO2e.
Fresenius has established significant climate commitments. The company aims to achieve climate neutrality by 2040. Furthermore, it has set a target to reduce its absolute Scope 1 and Scope 2 emissions by 50% by 2030, using 2020 as the baseline year. Fresenius Medical Care, a part of the group, has specific targets to reduce its Scope 1 emissions by 30% from a 2020 baseline by 2030, and to reduce its Scope 1 and 2 emissions to near zero by the middle of this decade (2025). The company also has a long-term ambition to achieve net zero across its entire value chain (Scope 1 to 3) by 2050, with plans to eliminate at least 90% of avoidable greenhouse gas emissions.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Fresenius’s Climate Goals (2030 & 2050)
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
10 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Fresenius
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project